A dual prognostic role for the TGFβ receptors in human breast cancer

详细信息    查看全文

• 作者：Ibrahim Y. Hachim ; MBChB ; MSc^a ; ¹ ; ^{Ibrahim.Hachim@mail.mcgill.ca" class="auth_mail" title="E-mail the corresponding author} ; Mahmood Y. Hachim ; MBChB ; MSc^b ; ¹ ; ^{mahmood.hachim@mail.mcgill.ca" class="auth_mail" title="E-mail the corresponding author} ; Vanessa M. Ló ; pez-Ozuna ; MBBS^a ; ^{vanessa.lopez2@mail.mcgill.ca" class="auth_mail" title="E-mail the corresponding author} ; Suhad Ali ; PhD^a ; ^{Suhad.Ali@mcgill.ca" class="auth_mail" title="E-mail the corresponding author} ; Jean-Jacques Lebrun ; PhD^a ; ^b ; ^{JJ.Lebrun@mcgill.ca" class="auth_mail" title="E-mail the corresponding author}
• 关键词：TGFβ ; Breast cancer ; Prognosis ; Molecular subtypes ; TGFβ receptors ; Patient outcomes
• 刊名：Human Pathology
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：57
• 期：Complete
• 页码：140-151
• 全文大小：1929 K

文摘

The transforming growth factor–β (TGFβ) plays a dual role in breast cancer, acting as a tumor suppressor in early carcinomas while promoting tumor metastasis in more advanced breast carcinoma. As a result, the prognostic role of TGFβ and its signaling components in breast cancer remains unclear. Here we evaluated the expression levels of TGFβ signaling receptors TβRII and TβRI using human breast cancer tissue microarrays and a large publicly available gene profiling database in relation to various clinicopathological parameters. Our results indicate that breast cancer tissues express lower TβRII and TβRI protein levels compared with normal breast tissue. In contrast to TβRI expression, TβRII mRNA expression levels were also significantly downregulated in invasive breast cancer compared with normal breast tissue (4.18-fold downregulation, P = 9.3 × 10^- 115). Interestingly, within the cancer cases analyzed, our results revealed a direct correlation between high TβRII and TβRI expression levels and classic poor prognostic clinicopathological parameters, including larger tumor size, advanced tumor stage, and poorly differentiated tumors. Next, we examined TGFβ receptors’ expression in relation to breast cancer molecular subtypes. Importantly, our results revealed that whereas expression of TGFβ receptors in luminal A and triple-negative breast cancer showed no correlation with patient outcome, their expression in luminal B and HER2 subtypes showed significant association with favorable patient outcome. Together, these results indicate that although TGFβ receptors are downregulated in breast cancer, their expression in tumors is an indicator of aggressive breast cancer phenotype. Moreover, the relation between TGFβ pathway and patient outcome is breast cancer subtype dependent.